The growing resistance to antibiotics has prompted the world to rediscover phages. Under the leadership of young innovator Rati Golijashvili, BioChimPharm is writing a new chapter in the history of medicine. This presents a golden opportunity for Georgia, the birthplace of bacteriophage technology.
Rati Golijashvili is the Master of Public Health (MPH), innovator and healthcare entrepreneur who has dedicated his career to combating the global crisis of antimicrobial resistance (AMR).
Born and raised in Tbilisi, Georgia, in a family of microbiologists and pharmacists, Rati developed a lifelong passion for biotechnology, healthcare, and innovation.
He is a Forbes 30under30, TEDxSpeaker, General Director of BioChimPharm, Board Chairman at Georgian Biopharmaceutical Cluster, and Board member at Georgian Pharmaceutical Association.
Rati is an innovator behind the groundbreaking novel antibiotics (Phage medications) platform that effectively and sustainably substitutes antibiotics to treat resistant infections.
As the General Director of BioChimPharm, a leading biopharmaceutical company based in Georgia that focuses on research, innovation, and production of bacteriophage, or phage pharmaceutical products, Rati leads the family business at BioChimPharm, which is based on the historical and oldest factory in the world, established in 1934 and fully dedicated to R&D and production of sustainable alternative to antibiotics.
The story was featured in FORBES USA as part of the “World of Forbes” chapter, alongside inspiring entrepreneurial stories from Forbes editions around the globe. “Building on the foundation of the world’s first historic phage factory (1934), at BioChimPharm we create and manufacture GMP-compliant phage pharmaceuticals for the treatment and prevention of antibiotic-resistant infections. We are revolutionizing global access to life-saving phage therapy.” Rati Golijashvili
BioChimPharm Opens the €6.5 Million Novel Antibiotics’ Manufacturing Plant Against Antimicrobial Resistance
BioChimPharm Invested EUR 6.5 million to develop high-tech pharmaceutical manufacturing plant to produce Novel Antibiotics against resistant infections Under Rati’s leadership, his company developed a first-of-its-kind, high-tech, sterile manufacturing facility in 2022 to increase its production capacity (up to 30 million vials) of novel antibiotics to better address the dramatically increasing trend of resistant infections. This facility was aimed at better fighting the AMR crisis and preparedness for future pandemics.
With Rati’s vision and expertise, the company was able to significantly increase its production capacity of life-saving novel antibiotics. The novel antibiotics provided by the company have helped millions of patients suffering from antibiotic-resistant infections regionally and globally.
The company extends its heartfelt appreciation to its dear local and international partners: European Union, EBRD, Enterprise Georgia, FAO, ProCredit Bank, and GITA for paricipation in EUR 6,5 million modernization project at the historic phage manufacturing facility in Tbilisi, dating back to 1934, where life-saving, phage-based novel antibiotics with European precision and quality are now being produced. This project of modernization would not have been possible without their support. To honor their significant contributions, the company proudly introduces the PHAGE AWARD, recognizing their outstanding commitment to fighting antimicrobial resistance and advancing phage technology.
European Union Ambassador to Georgia, Mr. Paweł Herczyński
EBRD Regional Director, Catarina Bjorlin Hansen
FAO Programme Coordinator, Javier Sanz Alvarez
Chairman at GITA – Georgia’s Innovation and Technology Agency, Avtandil Kasradze
Deputy Minister of Economy and Sustainable Development of Georgia, Mr. Irakli Nadareishvili
Food and Agriculture Organization, the FAO Georgia team
Ministry of Economy
European Union Ambassador to Georgia, Mr. Paweł Herczyński and Team Leader Economic Development and Trade, Mr. Dominik Papenheim
He is the the Chairman at Georgian BioPharmaceutical Cluster and a Board Member at Georgian Pharmaceutical Association.
Apart from leading his own company, Rati has also been a leading voice in advocating for the biopharmaceutical industry of Georgia. As the Chairman of the Georgian Biopharmaceutical Cluster and a Board Member of the Georgian Pharmaceutical Association, he has played a vital role in the growth and development of the entire sector.
Rati’s work in the field of biotechnology and bacteriophage has made a significant contribution to the fight against antibiotic resistance, and his efforts earned him a spot on the Forbes 30 Under 30 list twice – in Science (2018) and in Manufacturing & Industry (2019).
He is also a jury member 2022 for the same list, recognizing and supporting the achievements of young scientists who are making an impact in their respective fields.
Rati Golijashvili, a recently joined member, has proven to be an invaluable addition to the advisory board for the Education and Science Committee in the Parliament of Georgia. The committee’s strategic vision and action plan are centered around four key areas: developing policy documents and legislation, conducting oversight activities, managing public relations and communication, and enhancing organizational development. Since joining the board in 2023, Rati has been actively involved in the working process and has made significant contributions to advancing education and fostering innovation within the country.
Among his hundreds of media appearances on local and international communication channels and platforms, Rati highlighted the critical danger that antibiotic resistance poses to civilization in his TED speech (2019).
Although it may be a lesser-known issue, AMR causes 25,000 deaths in Europe alone, 35,000 deaths in the United States, and up to 700,000 deaths worldwide every year.
Recent high-profile reports backed by the British Government suggest that by 2050, the annual casualties due to antibacterial resistance may exceed 10 million, with the economic costs to society reaching 100 trillion US dollars, if no action is taken to reverse the trend.
Developed By My Software © 2023 All Rights Reserved.